Pharmosa Biopharm Inc. (TPEX:6875)
Taiwan · Delayed Price · Currency is TWD 38.40
+0.60 (1.59%)
Aug 12, 2025, 1:28 PM CST
Pharmosa Biopharm Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2020 |
| 173.63 | 167.57 | 314.5 | - | - | - | Upgrade | |
Revenue Growth (YoY) | -46.43% | -46.72% | - | - | - | - | Upgrade |
Cost of Revenue | 46.68 | 40.67 | - | - | - | - | Upgrade |
Gross Profit | 126.95 | 126.9 | 314.5 | - | - | - | Upgrade |
Selling, General & Admin | 46.87 | 50.69 | 40.35 | 29.22 | 18.32 | 12.11 | Upgrade |
Research & Development | 359.14 | 294.79 | 276.97 | 242.31 | 240.81 | 175.31 | Upgrade |
Operating Expenses | 406.01 | 345.47 | 317.32 | 271.53 | 259.12 | 187.42 | Upgrade |
Operating Income | -279.06 | -218.57 | -2.82 | -271.53 | -259.12 | -187.42 | Upgrade |
Interest Expense | -2.3 | -2.42 | -2.86 | -0.65 | -1.21 | -3.86 | Upgrade |
Interest & Investment Income | 35.6 | 32.07 | 9.53 | 0.5 | 0.1 | 0.04 | Upgrade |
Earnings From Equity Investments | -0.64 | 1.95 | 5.5 | 3.93 | 0.66 | 4.63 | Upgrade |
Currency Exchange Gain (Loss) | 19.31 | 19.31 | -6.68 | 1.02 | 0.2 | 0.96 | Upgrade |
Other Non Operating Income (Expenses) | -54.69 | 1.16 | 5.79 | 0.23 | 2.89 | 3.96 | Upgrade |
EBT Excluding Unusual Items | -281.78 | -166.49 | 8.46 | -266.51 | -256.48 | -181.7 | Upgrade |
Gain (Loss) on Sale of Assets | -0.34 | -0.34 | - | - | - | - | Upgrade |
Other Unusual Items | 0.18 | 0.18 | - | - | - | - | Upgrade |
Pretax Income | -281.94 | -166.65 | 8.46 | -266.51 | -256.48 | -181.7 | Upgrade |
Net Income | -281.94 | -166.65 | 8.46 | -266.51 | -256.48 | -181.7 | Upgrade |
Net Income to Common | -281.94 | -166.65 | 8.46 | -266.51 | -256.48 | -181.7 | Upgrade |
Shares Outstanding (Basic) | 129 | 126 | 113 | 99 | 85 | 48 | Upgrade |
Shares Outstanding (Diluted) | 129 | 126 | 113 | 99 | 85 | 48 | Upgrade |
Shares Change (YoY) | 7.59% | 11.49% | 15.09% | 16.02% | 78.34% | 27.94% | Upgrade |
EPS (Basic) | -2.19 | -1.32 | 0.07 | -2.70 | -3.02 | -3.82 | Upgrade |
EPS (Diluted) | -2.19 | -1.32 | 0.07 | -2.70 | -3.02 | -3.82 | Upgrade |
Free Cash Flow | -433.37 | -292.43 | -50.01 | -268.47 | -240.57 | -188.5 | Upgrade |
Free Cash Flow Per Share | -3.36 | -2.31 | -0.44 | -2.73 | -2.83 | -3.96 | Upgrade |
Gross Margin | 73.11% | 75.73% | 100.00% | - | - | - | Upgrade |
Operating Margin | -160.72% | -130.44% | -0.90% | - | - | - | Upgrade |
Profit Margin | -162.38% | -99.45% | 2.69% | - | - | - | Upgrade |
Free Cash Flow Margin | -249.59% | -174.51% | -15.90% | - | - | - | Upgrade |
EBITDA | -262.31 | -205.09 | 2.99 | -266.24 | -254.73 | -184.2 | Upgrade |
EBITDA Margin | -151.07% | -122.39% | 0.95% | - | - | - | Upgrade |
D&A For EBITDA | 16.76 | 13.48 | 5.81 | 5.3 | 4.39 | 3.22 | Upgrade |
EBIT | -279.06 | -218.57 | -2.82 | -271.53 | -259.12 | -187.42 | Upgrade |
EBIT Margin | -160.72% | -130.44% | -0.90% | - | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.